Replicating genotype-phenotype associations Chanock et al., Nature 2007

Fine Mapping versus Replication in Whole-Genome Association Studies Clarke et al., AJHG 2007

Mari Nelis

Bioinfo J.Club Nov. 2007



Replicated studies

Diabetes - peroxisome proliferator-activated receptor-γ (PPARG) and transcription factor TCF7L2

Crohn's disease – nucleotide-binding oligomerization domain containing 2 (NOD2)

Age-related macular degeneration – complement factor H (CFH)

Prostate cancer risk – chromosome region 8q24

Instances of non-replication

- Small sample size
- Poor study design lack of comparability between cases and controls
- Follow-up studies analyze different variants

Extremely small p-values in GWA studies should be interpreted carefully

Genotyping of ancestry informative markers

Publish the results of initial study, give correct description of sample collection, genotyping, statistical analysis

Publish negative findings



Disease prevalence – 0.05

Genotype relative risk – 1.3

Freq of high-risk allele – 0.25

First stage

500 000 markers -> 3000 cases, 3000 controls

Replication study

K=10 regions

1500 cases, 1500 controls

Type I error rate – 0.05

Bonferroni corrected rate $\alpha' = 0.05/[10x(50-m+1)]$ (true markers are dependent)

 $\alpha' = 0.05/(10x50)$ (true markers are independent)





One of the selected markers is in perfect LD with causal variant







Maximum probability that a locus exceeds the significance threshold in a replication study but is different from the locus initially identified

Conclusions

The effectiveness of the local strategy increases with the number and strength of true markers among the additional markers included in the replicate study

When the original marker is strongly associated with disease (either because there is a large effect or because it is highly correlated with the causal variant) then an exact strategy is the best approach